Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 2/20 | 0.48 |
| ▸ | CMA1 | P23946 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 2/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 2/20 | 0.40 |
| ▸ | F11 | P03951 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | F7 | P08709 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | F3 | P13726 | 1/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207489 | 0.84 | F7 (0.50) | AHRCMA1NOS1DYRK1AALDH1A1 | |
| SCHEMBL2715277 | 0.73 | ALDH1A1 (0.39) | ALDH1A1HPGDTSHRHSD17B10GRIN2D | |
| SCHEMBL6959510 | 0.73 | TYR (0.48) | ALOX15POLBTSHRHSD17B10GAA | |
| SCHEMBL207534 | 0.73 | AHR (0.48) | AHRNOS1DYRK1AALDH1A1CYP2A6 | |
| SCHEMBL207104 | 0.73 | AHR (0.48) | AHRALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL207188 | 0.73 | CYP1A2 (0.46) | ALDH1A1HPGDPOLBHSD17B10DAO | |
| SCHEMBL207242 | 0.71 | ALDH1A1 (0.56) | ALDH1A1HPGDDAOGRIN2DGRIN3B | |
| SCHEMBL6959490 | 0.68 | APP (0.45) | ALDH1A1ALOX15TSHRHSD17B10KDM4E | |
| SCHEMBL6958413 | 0.68 | CYP1A2 (0.45) | ALDH1A1DAOCYP2A6KDM4ECYP1A2 | |
| SCHEMBL6354139 | 0.68 | GAA (0.43) | CYP2A6GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3321262-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2021-01-13 | — | — | EP | claimed |
| CN-106349217-B | Serine/threonine kinase inhibitors | 阵列生物制药公司 | 2020-08-28 | — | — | CN | claimed |
| CN-111170954-A | Phenalenone compounds and application thereof | 大连理工大学 | 2020-05-19 | — | — | CN | claimed |
| EP-3321262-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2018-05-16 | — | — | EP | claimed |
| US-20180127393-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-05-10 | — | — | US | claimed |
| US-9259470-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-02-16 | — | — | US | claimed |
| EP-2820009-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2015-01-07 | — | — | EP | claimed |
| US-20140249127-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2014-09-04 | — | — | US | claimed |
| US-8697715-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA, INC. (US) | 2014-04-15 | — | — | US | claimed |
| US-20130252934-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-09-26 | — | — | US | claimed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | claimed |
| US-6759428-B2 | SUCH AS N-((1,2)-2-(((CYANO(CYCLOPROPYL)METHYL)AMINO)CARBONYL) CYCLOHEXYL)-1H-INDOLE-2-CARBOXAMIDE; CATHEPSIN K INHIBITORS | ROCHE PALO ALTO LLC | 2004-07-06 | — | — | US | claimed |
| US-20040122063-A1 | Ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-24 | — | — | US | claimed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | claimed |
| US-20040077646-A1 | Indole nitriles | ROCHE PALO ALTO LLC | 2004-04-22 | — | — | US | claimed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | claimed |
| EP-1373204-A2 | HETEROCYCLIC COMPOUNDS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2004-01-02 | — | — | EP | claimed |
| EP-1270557-A1 | ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-01-02 | — | — | EP | claimed |
| WO-2002072548-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS HISTAMINE H4 LIGANDS. | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-09-19 | — | — | WO | claimed |
| US-5210022-A | Substrates sensitive to beta-galactosidase and beta-glucuronidase, quantitative analysis | RCR SCIENTIFIC, INC. (US) | 1993-05-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | AHR 3277/4885CMA1 2177/4885NOS1 151/4885 |
| US-20040077646-A1 | Indole nitriles | TPH1, IDO1, NAT1 | AHR 202/4885CMA1 4/4885NOS1 7/4885 |
| US-20140249127-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K11, TTBK1 | AHR 4684/4885CMA1 2031/4885NOS1 1826/4885 |
| US-20180127393-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K11, TTBK1 | AHR 4684/4885CMA1 2031/4885NOS1 1826/4885 |
| US-20130252934-A1 | SERINE/THREONINE KINASE INHIBITORS | MAP3K1, MAP3K11, TTBK1 | AHR 4684/4885CMA1 2031/4885NOS1 1826/4885 |
| US-20040122063-A1 | Ethylenediamine derivatives | ECE1, F2, ECE2 | AHR 1893/4885CMA1 1162/4885NOS1 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.